Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

Tan DHS, Rolon MJ, Figueroa MI, Sued O, Gun A, Kaul R, Raboud JM, Szadkowski L, Hull MW, Walmsley SL, Cahn P; Argentinean GARDEL research network.

PLoS One. 2019 Sep 6;14(9):e0221653. doi: 10.1371/journal.pone.0221653. eCollection 2019.

2.

Drug interactions are not always predictable: the curious case of valproic acid and dolutegravir and a possible explanation.

Tseng AL, Wong AYJ, McLelland CJ, Walmsley SL.

AIDS. 2019 Aug 1;33(10):1677-1679. doi: 10.1097/QAD.0000000000002256. No abstract available.

PMID:
31305336
3.

Heart Failure With Preserved Ejection Fraction in Women Living With HIV: Another Inflammatory Comorbidity?

Moayedi Y, Walmsley SL.

J Infect Dis. 2019 Apr 22. pii: jiz185. doi: 10.1093/infdis/jiz185. [Epub ahead of print] No abstract available.

PMID:
31100123
4.

Lymphocytic colitis in an HIV positive patient: is dolutegravir the cause?

Mclelland CJ, Tseng AL, Walmsley SL, Chakrabarti S.

AIDS. 2019 Jun 1;33(7):1265-1266. doi: 10.1097/QAD.0000000000002203. No abstract available.

PMID:
31045946
5.

Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.

Tan DHS, Raboud JM, Szadkowski L, Grinsztejn B, Madruga JV, Figueroa MI, Cahn P, Barton SE, Clarke A, Fox J, Zubyk W, Walmsley SL; VALIDATE Study Group .

J Antimicrob Chemother. 2019 Feb 1;74(2):480-488. doi: 10.1093/jac/dky433.

6.

Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression.

Almeida-Brasil CC, Moodie EEM, McLinden T, Hamelin AM, Walmsley SL, Rourke SB, Wong A, Klein MB, Cox J.

AIDS. 2018 Jun 19;32(10):1323-1332. doi: 10.1097/QAD.0000000000001822.

PMID:
29683846
7.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
8.

Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis.

McLinden T, Moodie EEM, Hamelin AM, Harper S, Rossi C, Walmsley SL, Rourke SB, Cooper C, Klein MB, Cox J.

Drug Alcohol Depend. 2018 Apr 1;185:374-380. doi: 10.1016/j.drugalcdep.2017.12.031. Epub 2018 Feb 20.

PMID:
29544189
9.

Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.

Rossi C, Saeed S, Cox J, Vachon ML, Martel-Laferrière V, Walmsley SL, Cooper C, Gill MJ, Hull M, Moodie EEM, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2018 Mar 27;32(6):751-759. doi: 10.1097/QAD.0000000000001750.

10.

Elevated Levels of Estradiol in Human Immunodeficiency Virus-Infected Pregnant Women on Protease Inhibitor-Based Regimens.

Balogun KA, Guzman Lenis MS, Papp E, Loutfy M, Yudin MH, MacGillivray J, Walmsley SL, Silverman M, Serghides L.

Clin Infect Dis. 2018 Jan 18;66(3):420-427. doi: 10.1093/cid/cix761.

11.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
12.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team.

Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Erratum in: Lancet HIV. 2017 Dec;4(12 ):e535.

PMID:
28729158
13.

Injection Drug Use, Unemployment, and Severe Food Insecurity Among HIV-HCV Co-Infected Individuals: A Mediation Analysis.

McLinden T, Moodie EEM, Hamelin AM, Harper S, Walmsley SL, Paradis G, Aibibula W, Klein MB, Cox J.

AIDS Behav. 2017 Dec;21(12):3496-3505. doi: 10.1007/s10461-017-1850-2.

PMID:
28726043
14.

Erratum to: Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial.

Siou K, Walmsley SL, Murphy KE, Raboud J, Loutfy M, Yudin MH, Silverman M, Ladhani NN, Papp E, Serghides L.

Pilot Feasibility Stud. 2017 Apr 28;3:21. doi: 10.1186/s40814-017-0135-x. eCollection 2017.

15.

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.

Squires KE, Young B, Santiago L, Dretler RH, Walmsley SL, Zhao HH, Pakes GE, Ross LL, Shaefer MS.

HIV AIDS (Auckl). 2017 Mar 3;9:51-61. doi: 10.2147/HIV.S108756. eCollection 2017.

16.

Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial.

Siou K, Walmsley SL, Murphy KE, Raboud J, Loutfy M, Yudin MH, Silverman M, Ladhani NN, Serghides L.

Pilot Feasibility Stud. 2016 Aug 12;2:49. eCollection 2016. Erratum in: Pilot Feasibility Stud. 2017 Apr 28;3:21.

17.

Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study.

Tan DH, Raboud J, Szadkowski L, Szabo E, Hu H, Wong Q, Cheung AM, Walmsley SL.

HIV Clin Trials. 2017 Jan;18(1):28-38. doi: 10.1080/15284336.2016.1266074. Epub 2016 Dec 13.

PMID:
27951753
18.
19.

HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.

Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, Loutfy M, Trottier S, Smaill F, Yudin MH, Klein M, Harris M, Cohen J, Wobeser W, Bitnun A, Lapointe N, Samson L, Brophy J, Karatzios C, Ogilvie G, Coutlée F, Raboud J; HPV in HIV Study Group.

Vaccine. 2016 Sep 14;34(40):4799-806. doi: 10.1016/j.vaccine.2016.08.016. Epub 2016 Aug 17.

PMID:
27544584
20.

What's new for antiretroviral treatment in women with HIV.

Andany N, Walmsley SL.

J Virus Erad. 2016 Apr 1;2(2):67-77.

21.

Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.

Kim CJ, Walmsley SL, Raboud JM, Kovacs C, Coburn B, Rousseau R, Reinhard R, Rosenes R, Kaul R.

HIV Clin Trials. 2016 Jul;17(4):147-57. doi: 10.1080/15284336.2016.1184827. Epub 2016 Jun 7.

PMID:
27267710
22.

Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis.

Costiniuk CT, Brunet L, Rollet-Kurhajec KC, Cooper CL, Walmsley SL, Gill MJ, Martel-Laferriere V, Klein MB.

Open Forum Infect Dis. 2016 Mar 7;3(2):ofw050. doi: 10.1093/ofid/ofw050. eCollection 2016 Mar.

23.

Differential predictors of ART adherence among HIV-monoinfected versus HIV/HCV-coinfected individuals.

Shuper PA, Joharchi N, Irving H, Fletcher D, Kovacs C, Loutfy M, Walmsley SL, Wong DK, Rehm J.

AIDS Care. 2016 Aug;28(8):954-62. doi: 10.1080/09540121.2016.1158396. Epub 2016 Mar 14.

PMID:
26971360
24.

Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities.

Cox J, Hamelin AM, McLinden T, Moodie EE, Anema A, Rollet-Kurhajec KC, Paradis G, Rourke SB, Walmsley SL, Klein MB; Canadian Co-infection Cohort Investigators.

AIDS Behav. 2017 Mar;21(3):792-802. doi: 10.1007/s10461-016-1326-9.

25.

HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Kis O, Sankaran-Walters S, Hoque MT, Walmsley SL, Dandekar S, Bendayan R.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2771-81. doi: 10.1128/AAC.02278-15. Print 2016 May.

26.

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?

Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferrière V, Hull M, Gill MJ, Cox J, Cooper C, Klein MB; Canadian Co-Infection Cohort Study, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haider S, Harris M, Haase D, Hull M, Montaner J, Moodie E, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall JM, Vachon ML, Walmsley S, Wong D.

Clin Infect Dis. 2016 Apr 1;62(7):919-926. doi: 10.1093/cid/civ1222. Epub 2016 Jan 6.

27.

Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.

Papp E, Balogun K, Banko N, Mohammadi H, Loutfy M, Yudin MH, Shah R, MacGillivray J, Murphy KE, Walmsley SL, Silverman M, Serghides L.

J Infect Dis. 2016 May 15;213(10):1532-40. doi: 10.1093/infdis/jiw004. Epub 2016 Jan 5.

28.

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.

Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, Currier JS.

Open Forum Infect Dis. 2015 Apr 26;2(2):ofv059. doi: 10.1093/ofid/ofv059. eCollection 2015 Apr.

29.

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.

Kandel CE, Walmsley SL.

Drug Des Devel Ther. 2015 Jul 7;9:3547-55. doi: 10.2147/DDDT.S84850. eCollection 2015. Review.

30.

Contraceptive options for HIV-positive women: making evidence-based, patient-centred decisions.

Sharma M, Walmsley SL.

HIV Med. 2015 Jul;16(6):329-36. doi: 10.1111/hiv.12221. Epub 2015 Feb 17. Review.

31.

Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.

Tan DH, Raboud JM, Szadkowski L, Yi TJ, Shannon B, Kaul R, Liles WC, Walmsley SL.

AIDS Res Hum Retroviruses. 2015 Mar;31(3):276-81. doi: 10.1089/AID.2014.0183. Epub 2014 Dec 17.

32.

HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

Papp E, Mohammadi H, Loutfy MR, Yudin MH, Murphy KE, Walmsley SL, Shah R, MacGillivray J, Silverman M, Serghides L.

J Infect Dis. 2015 Jan 1;211(1):10-8. doi: 10.1093/infdis/jiu393. Epub 2014 Jul 16.

33.

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, Walmsley SL, McCreath H, Milne GL, Sanchez SC, Currier JS, Lake JE.

Mediators Inflamm. 2014;2014:803095. doi: 10.1155/2014/803095. Epub 2014 Jun 1.

34.

Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance.

Kuster SP, Rudnick W, Shigayeva A, Green K, Baqi M, Gold WL, Lovinsky R, Muller MP, Powis JE, Rau N, Simor AE, Walmsley SL, Low DE, McGeer A; Toronto Invasive Bacterial Diseases Network.

Clin Infect Dis. 2014 Oct;59(7):944-52. doi: 10.1093/cid/ciu497. Epub 2014 Jun 27.

PMID:
24973312
35.

In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents.

Kis O, Walmsley SL, Bendayan R.

Pharm Res. 2014 Sep;31(9):2404-19. doi: 10.1007/s11095-014-1336-0. Epub 2014 Mar 5.

PMID:
24595498
36.

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.

Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, Stramotas SA, Tracy R, Currier JS.

HIV Med. 2014 Aug;15(7):431-41. doi: 10.1111/hiv.12128. Epub 2014 Feb 10.

37.

Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: an observational cohort study.

Tan DH, Raboud JM, Kaul R, Walmsley SL.

BMJ Open. 2014 Jan 24;4(1):e004210. doi: 10.1136/bmjopen-2013-004210.

38.

Raltegravir as antiretroviral therapy in HIV/AIDS.

Sharma M, Walmsley SL.

Expert Opin Pharmacother. 2014 Feb;15(3):395-405. doi: 10.1517/14656566.2014.868884. Epub 2013 Dec 4. Review.

PMID:
24304203
39.

The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada.

Kennedy VL, Serghides L, Raboud JM, Su D, Blitz S, Hart TA, Walmsley SL, Angel JB, Smaill FM, Ralph ED, Tharao WE, Loutfy MR; Ontario HIV Fertility Research Team.

AIDS Care. 2014;26(6):777-84. doi: 10.1080/09540121.2013.855295. Epub 2013 Nov 9.

PMID:
24206065
40.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541.

41.

Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.

Tan DH, Murphy K, Shah P, Walmsley SL.

BMC Infect Dis. 2013 Oct 28;13:502. doi: 10.1186/1471-2334-13-502. Review.

42.

Caring for women living with HIV: gaps in the evidence.

Loutfy MR, Sherr L, Sonnenberg-Schwan U, Walmsley SL, Johnson M, d'Arminio Monforte A; Women for Positive Action.

J Int AIDS Soc. 2013 Oct 1;16:18509. doi: 10.7448/IAS.16.1.18509. Review.

43.

Self-Reported Preconception Care of HIV-Positive Women of Reproductive Potential: A Retrospective Study.

Loutfy MR, Blitz S, Zhang Y, Hart TA, Walmsley SL, Smaill FM, Rachlis AR, Yudin MH, Angel JB, Ralph ED, Tharao W, Raboud JM; Ontario HIV Fertility Research Team.

J Int Assoc Provid AIDS Care. 2014 Sep-Oct;13(5):424-33. doi: 10.1177/2325957413494238. Epub 2013 Aug 5.

PMID:
23918921
44.

Management of persons infected with human immunodeficiency virus requiring admission to the intensive care unit.

Tan DH, Walmsley SL.

Crit Care Clin. 2013 Jul;29(3):603-20. doi: 10.1016/j.ccc.2013.03.010. Epub 2013 May 8. Review.

PMID:
23830655
45.

Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.

Loutfy MR, Walmsley SL, Klein MB, Raboud J, Tseng AL, Blitz SL, Pick N, Conway B, Angel JB, Rachlis AR, Gough K, Cohen J, Haase D, Burdge D, Smaill FM, de Pokomandy A, Loemba H, Trottier S, la Porte CJ.

BMC Infect Dis. 2013 Jun 3;13:256. doi: 10.1186/1471-2334-13-256.

46.

Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection.

Tan DH, Raboud JM, Kaul R, Brunetta J, Kaushic C, Kovacs C, Lee E, Luetkehoelter J, Rachlis A, Smaill F, Smieja M, Walmsley SL.

Clin Infect Dis. 2013 Aug;57(3):448-57. doi: 10.1093/cid/cit208. Epub 2013 Apr 9.

PMID:
23572481
47.

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J; VIKING Study Group.

J Infect Dis. 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7.

48.

Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.

Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R.

Pharm Res. 2013 Apr;30(4):1050-64. doi: 10.1007/s11095-012-0942-y. Epub 2012 Dec 7.

PMID:
23224979
49.

A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS.

AIDS Patient Care STDS. 2012 Sep;26(9):532-40. doi: 10.1089/apc.2012.0135. Epub 2012 Jul 23.

50.

Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy.

Szadkowski L, Tseng A, Walmsley SL, Salit I, Raboud JM.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1579-83. doi: 10.1089/AID.2012.0018. Epub 2012 Aug 3.

PMID:
22734840

Supplemental Content

Loading ...
Support Center